Physician profile
Robert A Norman
NPI 1447272026
$6,247.78
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $646 · 2021: $1,403 · 2022: $743 · 2023: $1,522 · 2024: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Consulting Fee: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.06 |
| Consulting Fee | $1,180.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,858.57 | 2019-2024 | Bimzelx, Cimzia |
| Abbvie INC. | $1,148.11 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $397.19 | 2019-2024 | |
| Amgen INC. | $254.08 | 2019-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $214.36 | 2019-2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $206.46 | 2024 | Sotyktu |
| Genzyme Corporation | $202.32 | 2020-2024 | |
| Glaxosmithkline, LLC. | $123.45 | 2021 | |
| Janssen Biotech, INC. | $116.31 | 2019-2024 | Tremfya, Simponi, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.18 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $69.37 | 2021 | |
| Leo Pharma INC. | $68.80 | 2020 | |
| Sun Pharmaceutical Industries INC. | $60.76 | 2019-2024 | |
| Smith+Nephew, INC. | $59.58 | 2021 | |
| Lilly USA, LLC | $48.12 | 2022-2023 | Taltz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $46.60 | 2024 | Hyrimoz |
| Kerecis Limited | $46.23 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Incyte Corporation | $40.28 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $39.84 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $28.89 | 2024 | |
| Phadia US INC. | $20.43 | 2024 | Immunocap |
| Organogenesis INC. | $20.38 | 2021 | |
| Convatec INC. | $19.68 | 2024 | |
| Dusa Pharmaceuticals, INC. | $18.33 | 2019 | |
| Fresenius Kabi USA, LLC | $16.33 | 2023 | |
| Merck Sharp & Dohme LLC | $14.47 | 2019 | |
| Dermira, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.